German construction sector still in recession, civil engineering only bright spot
SALT LAKE CITY - Sera Prognostics Inc. (NASDAQ:SERA), a $116 million market cap pregnancy biomarker testing company, has appointed Dr. Tiffany Inglis as Chief Medical Officer, the company announced Wednesday. According to InvestingPro data, while Sera maintains a strong balance sheet with more cash than debt, the company faces near-term profitability challenges with analysts projecting losses for the current year.
Dr. Inglis joins Sera with prior experience in clinical leadership positions at Elevance Health and Carelon Health, where she focused on women’s and children’s health programs. She will lead Sera’s clinical operations as the company works to expand adoption of its PreTRM Test, which predicts preterm birth risk. InvestingPro analysis indicates significant growth potential, with analysts forecasting a 247% revenue increase for fiscal year 2025, though the company’s current gross profit margins remain under pressure.
"As an OBGYN, Dr. Inglis understands the importance of delivering real-time, actionable information to patients that can achieve healthier outcomes for both mom and baby," said Zhenya Lindgardt, CEO of Sera Prognostics, in a press release statement.
Dr. Inglis received her medical degree from the Medical College of Ohio in 2002 and completed an Obstetrics and Gynecology residency at Riverside Methodist Hospital in Columbus, Ohio. She practiced as an OBGYN throughout Ohio for over a decade.
The appointment comes as Sera prepares for publication of its PRIME study and launches pilots with state Medicaid programs for its PreTRM Test, which measures proteins in blood samples taken during weeks 18-20 of pregnancy to assess preterm birth risk.
Preterm birth, defined as birth before 37 weeks gestation, affects more than one in ten infants in the United States according to the 2024 March of Dimes Report Card. It is associated with increased risk of long-term medical complications and significant healthcare costs.
Sera Prognostics, headquartered in Salt Lake City, focuses on developing diagnostic tests for pregnancy complications with the goal of improving maternal and neonatal health outcomes. With a current ratio of 1.73, the company maintains adequate liquidity for its operations. Investors seeking deeper insights into Sera’s financial health and growth prospects can access comprehensive analysis through InvestingPro, which offers detailed metrics and additional ProTips for informed investment decisions.
In other recent news, Sera Prognostics announced its second quarter 2025 earnings, showcasing a notable improvement in its earnings per share (EPS). The company reported an EPS of -$0.16, which exceeded analysts’ expectations of -$0.23. Despite this positive earnings surprise, Sera Prognostics’ revenue significantly underperformed, with actual revenue reaching only $17,000 compared to the anticipated $100,000. This earnings report highlights a mixed financial performance for the company. While the EPS beat is a positive development, the revenue shortfall may raise concerns among investors. These recent developments could influence analysts’ future evaluations and recommendations for Sera Prognostics. As the company navigates these financial results, investors will likely keep a close eye on its next moves.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.